DEFM14A: Royalty Pharma to Internalize Management in $200 Million Deal, Seeks Shareholder Approval

Royalty Pharma plans to acquire its external manager, RP Management, LLC, for $200 million in cash and 24,530,266 non-voting shares, aiming to streamline operations and enhance shareholder value.

Summary

• Royalty Pharma plc is seeking shareholder approval for a series of proposals at its upcoming Annual General Meeting and Special Meeting of Shareholders on May 12, 2025.
• The most significant proposal involves the acquisition of its external manager, RP Management, LLC (RPM), in a transaction valued at $200 million in cash and 24,530,266 non-voting shares of Royalty Pharma Holdings Ltd. (RPH).
• RPH will also assume RPM's $380 million term loan facility.
• The meeting will also address the adoption of the 2025 Equity Incentive Plan, election of directors, executive compensation, and ratification of the independent accounting firm.
• Shareholders are encouraged to vote on these proposals, which the Board unanimously recommends in favor of.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook on the internalization transaction, highlighting expected financial benefits and enhanced shareholder value. The Board's unanimous recommendation and management's excitement contribute to the positive sentiment.

Positives

• The internalization transaction is expected to result in significant cash savings, estimated to be over $100 million in 2026 and $175 million in 2030.
• The transaction is projected to be immediately accretive to Portfolio Cash Flow per share.
• The acquisition simplifies Royalty Pharma's corporate structure, enhancing transparency and comparability.
• The new structure strengthens alignment between management and shareholders through equity vesting.
• All RPM employees will become part of the integrated company, ensuring continuity of operations and personnel.

Negatives

• The Share Consideration (and related Class B Consideration) received by Mr. Legorreta is subject to vesting on a straight-line basis over five years and any unvested shares are subject to forfeiture under certain conditions.
• The success of the integration of Royalty Pharma and RP LLC is not guaranteed, and the anticipated benefits may not be fully realized or may take longer than expected.
• The transaction is subject to regulatory approvals, and there is a risk that these approvals may not be obtained or may be delayed.

Risks

• Integration risks associated with combining Royalty Pharma and RP LLC.
• Potential delays in obtaining regulatory approvals.
• Risk that the anticipated benefits of the transaction may not be fully realized.
• Dependence on key personnel and the potential loss of key employees.
• The risk that Royalty Pharmas Shareholders may not approve the Internalization Proposal.

Future Outlook

Royalty Pharma anticipates significant cash savings and enhanced shareholder value through the internalization of its management structure.

Management Comments

• We are excited about the tremendous opportunities ahead for Royalty Pharma to drive value creation and long-term growth.
• Through our work, we are committed to deliver positive impacts to all our shareholders.

Industry Context

The internalization trend is becoming more common in the asset management industry as companies seek to reduce costs and improve alignment with shareholders.

Comparison to Industry Standards

• The document references comparable acquisition transactions in the alternative asset management industry, with a median LTM AV/EBITDA multiple of 17.9x.
• Comparable companies mentioned include The Blackstone Group, KKR & Co. Inc., and Apollo Global Management, LLC.

Related Party Transactions

• The document discloses related party transactions, including the management agreement with RPM and the ownership of the EPA Holdings Entities by Mr. Legorreta.

Stakeholder Impact

• Shareholders are expected to benefit from increased value creation and long-term growth.
• Employees of RPM will become part of the integrated company, ensuring long-term continuity.
• Customers and partners will experience a more streamlined and efficient organization.

Next Steps

• Shareholder vote on the proposals at the Annual General Meeting and Special Meeting of Shareholders on May 12, 2025.
• Completion of the acquisition of RP Management, LLC, expected by the end of the second quarter of 2025, pending regulatory approvals.
• Implementation of the 2025 Equity Incentive Plan, subject to shareholder approval.

Key Dates

Keywords

Royalty Pharma, RP Management, Internalization, Shareholder Meeting, Acquisition, Financial Performance, Equity Incentive Plan, Corporate Governance, Proxy Statement, Transaction